X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 364.8 32.8 1,113.2% View Chart
P/BV x 18.0 6.1 294.8% View Chart
Dividend Yield % 1.6 0.8 208.0%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-16
CADILA HEALTHCARE
Mar-17
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs982460 213.5%   
Low Rs556305 182.4%   
Sales per share (Unadj.) Rs252.992.1 274.6%  
Earnings per share (Unadj.) Rs62.114.8 419.4%  
Cash flow per share (Unadj.) Rs63.318.5 342.5%  
Dividends per share (Unadj.) Rs10.003.20 312.5%  
Dividend yield (eoy) %1.30.8 155.4%  
Book value per share (Unadj.) Rs363.668.0 534.8%  
Shares outstanding (eoy) m31.961,023.74 3.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.2 73.2%   
Avg P/E ratio x12.425.8 47.9%  
P/CF ratio (eoy) x12.220.7 58.7%  
Price / Book Value ratio x2.15.6 37.6%  
Dividend payout %16.121.6 74.5%   
Avg Mkt Cap Rs m24,580391,581 6.3%   
No. of employees `0000.816.9 4.5%   
Total wages/salary Rs m1,80115,002 12.0%   
Avg. sales/employee Rs Th10,748.95,594.5 192.1%   
Avg. wages/employee Rs Th2,395.2890.1 269.1%   
Avg. net profit/employee Rs Th2,641.1899.9 293.5%   
INCOME DATA
Net Sales Rs m8,08394,295 8.6%  
Other income Rs m8291,286 64.5%   
Total revenues Rs m8,91395,581 9.3%   
Gross profit Rs m23419,036 1.2%  
Depreciation Rs m373,750 1.0%   
Interest Rs m2450 0.4%   
Profit before tax Rs m1,02516,122 6.4%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-3 -56,543.3%   
Tax Rs m7521,289 58.3%   
Profit after tax Rs m1,98615,168 13.1%  
Gross profit margin %2.920.2 14.4%  
Effective tax rate %73.48.0 917.5%   
Net profit margin %24.616.1 152.7%  
BALANCE SHEET DATA
Current assets Rs m12,67860,223 21.1%   
Current liabilities Rs m2,43353,058 4.6%   
Net working cap to sales %126.77.6 1,668.0%  
Current ratio x5.21.1 459.1%  
Inventory Days Days3370 46.8%  
Debtors Days Days2288 25.5%  
Net fixed assets Rs m6972,984 0.1%   
Share capital Rs m1601,024 15.6%   
"Free" reserves Rs m11,46068,576 16.7%   
Net worth Rs m11,62169,600 16.7%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m14,400152,207 9.5%  
Interest coverage x570.536.8 1,549.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.6 90.6%   
Return on assets %13.810.3 134.5%  
Return on equity %17.121.8 78.4%  
Return on capital %23.617.9 131.5%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m18621,280 0.9%   
Fx outflow Rs m1,82110,874 16.7%   
Net fx Rs m-1,63510,406 -15.7%   
CASH FLOW
From Operations Rs m2,53113,495 18.8%  
From Investments Rs m-8,270-29,103 28.4%  
From Financial Activity Rs m-38623,158 -1.7%  
Net Cashflow Rs m-6,1257,556 -81.1%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 16, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS